Table 2.

Multivariable linear regression between either concentration anti-spike protein specific IgG, total relative avidity index (TRAI), antibody dependent cellular phagocytosis (ADCP) scores, or ACE2 inhibiting antibody concentrations specific to the index virus and participant demographic factors one-month post-second dose.

Output	Covariate	Coefficient (95% CI), P-value	P-value
Concentration anti-spike protein specific IgG	Vaccine series ChAdOx1-S/ ChAdOx1-S vs. mRNA/mRNA and ChAdOx1-S/mRNA combined	− 0.747 (− 0.965 to − 0.528)	< 0.001
	Vaccine interval (≥ 13 weeks vs. < 13 weeks)	− 0.384 (− 0.597 to − 0.170)	0.001
	Health status (Excellent vs. Very good/Good/Fair/Mildly poor combined)	− 0.226 (− 0.378 to − 0.073)	0.004
	Infection status (Previously infected vs. Infection-naïve)	0.369 (0.157 to 0.580)	0.001
TRAI	Vaccine series ChAdOx1-S/ChAdOx1-S vs. mRNA/mRNA and ChAdOx1-S/mRNA combined	− 0.060 (− 0.108 to − 0.012)	0.014
ADCP scores	Vaccine series ChAdOx1-S/ChAdOx1-S vs. mRNA/mRNA and ChAdOx1-S/mRNA combined	− 0.685 (− 0.860 to − 0.509)	< 0.001
	Health status (Excellent vs. Very good/Good/Fair/Mildly poor combined)	− 0.207 (− 0.330 to − 0.084)	0.001
	Infection status (Previously infected vs. Infection-naïve)	0.419 (0.249 to 0.588)	< 0.001
ACE2 inhibiting antibody concentrations	BMI (Normal and Underweight combined vs. Overweight and Obese combined)	− 0.196 (− 0.367 to − 0.025)	0.025
	Vaccine series ChAdOx1-S/ChAdOx1-S vs. mRNA/mRNA and ChAdOx1-S/mRNA combined	− 0.732 (− 0.974 to − 0.490)	< 0.001
	Vaccine interval (≥ 13 weeks vs. < 13 weeks)	− 0.401 (− 0.646 to − 0.156)	0.002
	Health status (Excellent vs. Very good/Good/Fair/Mildly poor combined)	− 0.240 (− 0.422 to − 0.057),	0.011

Data were log₁₀ transformed prior to statistical analyses. Confidence interval (CI). Coefficients from multivariable analyses correspond to log₁₀ transformed data.